Enzo Biochem, Inc. (ENZ)
NYSE: ENZ · IEX Real-Time Price · USD
1.160
+0.030 (2.65%)
Jun 14, 2024, 4:00 PM EDT - Market closed

Enzo Biochem Income Statement

Millions USD. Fiscal year is Aug - Jul.
Year 20232022202120202019 2018 - 1994
Revenue
31.0632.64117.7376.0281.17
Upgrade
Revenue Growth (YoY)
-4.85%-72.27%54.87%-6.34%-19.64%
Upgrade
Cost of Revenue
19.519.2164.1552.2557.92
Upgrade
Gross Profit
11.5713.4353.5823.7723.25
Upgrade
Selling, General & Admin
32.428.5249.6349.6947.27
Upgrade
Research & Development
3.92.443.254.453.18
Upgrade
Other Operating Expenses
0-0.500-28.93
Upgrade
Operating Expenses
36.330.4652.8954.1421.52
Upgrade
Operating Income
-24.74-17.030.69-30.371.73
Upgrade
Interest Expense / Income
1.12-0.18-0.01-0.45-1.06
Upgrade
Other Expense / Income
-46.151.41-7.18-1.390.3
Upgrade
Pretax Income
20.29-18.267.88-28.522.49
Upgrade
Net Income
20.29-18.267.88-28.522.49
Upgrade
Shares Outstanding (Basic)
4949484847
Upgrade
Shares Outstanding (Diluted)
4949484847
Upgrade
Shares Change
1.16%0.56%1.32%0.46%1.07%
Upgrade
EPS (Basic)
0.41-0.380.16-0.600.05
Upgrade
EPS (Diluted)
0.41-0.380.16-0.600.05
Upgrade
Free Cash Flow
-39.74-20.06-4.05-19.35-3.32
Upgrade
Free Cash Flow Per Share
-0.81-0.41-0.08-0.41-0.07
Upgrade
Gross Margin
37.24%41.14%45.51%31.27%28.64%
Upgrade
Operating Margin
-79.64%-52.16%0.59%-39.95%2.14%
Upgrade
Profit Margin
65.32%-55.94%6.69%-37.52%3.07%
Upgrade
Free Cash Flow Margin
-127.93%-61.46%-3.44%-25.45%-4.09%
Upgrade
EBITDA
24.09-15.6110.52-26.194.47
Upgrade
EBITDA Margin
77.56%-47.83%8.94%-34.46%5.51%
Upgrade
Depreciation & Amortization
2.682.832.652.783.04
Upgrade
EBIT
21.41-18.447.87-28.971.43
Upgrade
EBIT Margin
68.93%-56.49%6.68%-38.11%1.77%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).